News And Events

SEP 26, 2014

Provista Diagnostics to Participate in BTIG’s Inaugural Emerging Technologies in Healthcare Diagnostics Symposium

New York, NY – September 26, 2014 – Provista Diagnostics, Inc., a privately-held molecular diagnostics company focused on developing and commercializing proprietary blood-based diagnostic, prognostic and monitoring Laboratory Developed Tests (LDTs) designed to address the unmet needs in breast and gynecologic cancers affecting women, announces that David Reese, PhD, President and Chief Executive Officer is scheduled to participate in the inaugural BTIG Emerging Technologies in Healthcare Diagnostics Symposium being held September 29-30, 2014 at The Benjamin Hotel in New York City.

SEP 09, 2014

Provista Diagnostics, Inc. to Present at Rodman & Renshaw Annual Global Investment Conference

New York, NY – September 9, 2014 – Provista Diagnostics, Inc., a privately-held molecular diagnostics company focused on developing and commercializing proprietary blood-based diagnostic, prognostic and monitoring tests for cancers affecting women, today announces that David Reese, PhD, President and Chief Executive Officer, will deliver a corporate overview at the upcoming Rodman & Renshaw Annual Global Investment Conference taking place September 8 - 10, 2014 at the New York Palace Hotel.

SEP 08, 2014

Provista Diagnostics Announces Key Data Presented at the American Society of Clinical Oncologist Breast 2014 Annual Meeting 

Data Demonstrates the Ability of Serum Protein Biomarkers in Conjunction with Autoantibodies to Distinguish Between Invasive Breast Cancer and Benign Breast Conditions

New York, NY – September 8, 2014 – Provista Diagnostics, Inc., a privately-held molecular diagnostics company focused on developing and commercializing proprietary blood-based diagnostic, prognostic and monitoring tests for cancers affecting women, today announced data highlighting Provista’s proteomic diagnostic

AUG 18, 2014

Provista Diagnostics, Inc. Joins Personalized Medicine Coalition (PMC)

Provista is pleased to announce that is now a proud member of the Personalized Medicine Coalition (PMC).

JUL 15, 2014

Provista Diagnostics Completes Enrollment of its 001 Prospective Study of Protein-Based Biomarker Blood Test to Aid in Detection of Breast Cancer 

Prospective, Randomized, Multi-Center Study for Breast Cancer Detection in 351 Female Patients with Suspicious Breast Lesions

JUL 07, 2014

Provista Diagnostics, Inc. Appoints Rao V. Mulpuri, PhD, MBA, as Chief Operating Officer

New York, NY – July 7, 2014 – Provista Diagnostics, Inc., a molecular diagnostics company developing and commercializing proteomic-based diagnostic, prognostic and monitoring tests for cancers affecting women, today announced the appointment of Rao V. Mulpuri, PhD, MBA, as Chief Operating Officer (COO). In this role, Dr. Mulpuri will be responsible for leading and managing all aspects of the company's operations, including integration of the scientific and business functions, as well as quality and regulatory oversight to support the launch of Provista's pipeline of products.

JUN 26, 2014

Provista Diagnostics Laboratory Receives Accreditation from College of American Pathologists (CAP)

New York, NY – June 26, 2014 – Provista Diagnostics, Inc., a molecular diagnostics company delivering precision medicine to the medical community to fundamentally change the detection and management of women's cancers, today announced that its CLIA-certified laboratory in Scottsdale, AZ has received accreditation from the College of American Pathologists (CAP). Accreditation was awarded following a recent on-site inspection and is designed to ensure the highest standard of care for all laboratory patients.

JUN 07, 2014

Provista Diagnostics, Inc. Joins AdvaMed Dx

Provista is pleased to announce that is now a proud member of AdvaMed Dx.

MAY 27, 2014

Provista Diagnostics Expands Exclusive License Agreement for Biomarker Technologies Developed at the Biodesign Institute at Arizona State University

New York, NY – May 27, 2014 – Provista Diagnostics, Inc., a molecular diagnostics company developing and commercializing proteomic-based diagnostic, prognostic and monitoring tests for cancers affecting women, today announced it has expanded its exclusive license agreement for certain biomarker and autoantibody technologies identified by researchers Joshua LaBaer and Karen Anderson of the Biodesign Institute of Arizona State University.  The license provides Provista with access to patents, proprietary technology, materials, processing techniques and protocols necessary for detection of certain autoantibodies and use of certain biomarkers. 

MAY 19, 2014

Provista Diagnostics Announces First Patient Enrolled in Prospective, Proof-of-Concept Study of its Protein Biomarker Blood Test to Assess Presence of Breast Cancer

New York, NY – May 19, 2014 – Provista Diagnostics, Inc., a molecular diagnostics company developing and commercializing proteomic-based diagnostic, prognostic and monitoring tests for cancers affecting women, today announced that the first patient has been enrolled in the company’s 500-patient prospective study of an advanced version of its proteomic breast cancer assay. The assay will measure several protein biomarkers that can be obtained from a small blood sample, with the goal of developing a laboratory test that can assess, in conjunction with standard imaging and the physician’s clinical evaluation, the presence of breast cancer.